Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of excess liver triacylglycerol (TAG), inflammation, and liver damage. The goal of the present study was to directly quantify the biological sources of hepatic and plasma lipoprotein TAG in NAFLD. Patients (5 male and 4 female; 44 +/- 10 years of age) scheduled for a medically indicated liver biopsy were infused with and orally fed stable isotopes for 4 days to label and track serum nonesterified fatty acids (NEFAs), dietary fatty acids, and those derived from the de novo lipogenesis (DNL) pathway, present in liver tissue and lipoprotein TAG. Hepatic and lipoprotein TAG fatty acids were analyzed by gas chromatography/mass spectrometry. NAFLD patients were obese, with fasting hypertriglyceridemia and hyperinsulinemia. Of the TAG accounted for in liver, 59.0% +/- 9.9% of TAG arose from NEFAs; 26.1% +/- 6.7%, from DNL; and 14.9% +/- 7.0%, from the diet. The pattern of labeling in VLDL was similar to that in liver, and throughout the 4 days of labeling, the liver demonstrated reciprocal use of adipose and dietary fatty acids. DNL was elevated in the fasting state and demonstrated no diurnal variation. These quantitative metabolic data document that both elevated peripheral fatty acids and DNL contribute to the accumulation of hepatic and lipoprotein fat in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity seems to impair insulin signaling in hepatocytes, resulting in increased de novo hepatic lipogenesis and inhibited hepatic β-oxidation [141].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, although the major source of hepatocellular triglycerides are adipose tissue-derived NEFA, the rate of hepatic de novo lipogenesis is also much greater in MASLD, further contributing to intrahepatic lipid accumulation [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Remarkably, the major fraction of hepatocellular triglycerides in people with obesity and MASLD is not derived from non-esterified fatty acids (NEFA) provided by dietary lipids, but from circulating NEFA released from adipose tissue [17].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [17]
In the citing paper
“In individuals with MASLD and obesity, hepatic TG is reported to derive approximately 59% from circulating FFAs, 26% from DNL, and 15% from dietary sources [67].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [67]
In the citing paper
“IHTG was composed mainly of FFAs from SAT lipolysis (∼60%) and, to a lesser extent, FFAs from DNL (∼25%) or diet (∼15%).”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [23]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794 · cited 1×
“Given previous observations of higher fed-state DNL (23) and the known stimulatory effect of insulin on fatty acid synthesis (24), we were surprised that fed-state lipogenesis assessed at 1500 in tTRL TAG did not differ from values obtained in the fasting Figure 1 Model of lipid flux through the liver.”
ResultSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · cited 2×
“Insulin resistance has been shown to be associated with dysregulation of adiposederived fatty acid flux in the fasting state (10–12), and strong evidence exists demonstrating that in NAFLD patients, insulin does not suppress adipose tissue lipolysis to the same extent that it does in healthy individuals (13).”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 6×
“Dixon, J.B., Bhathal, P.S., and O’Brien, P.E. 2001.”
Influential
Research works printed but not linked: 6
- Donnelly, 2004, Diabetes., 56, A53
- 10.2337/diabetes.53.3.521 · DOI · Paper page
- Barrows, 2004, Diabetes., 56, A1388
- Timlin, 2004, Diabetes., 56, A338
- Baar, 2005, Am. J. Physiol., 288, E187
- Hellerstein, 1993, Am. J. Physiol., 265, E814
Cited by
Items 301–400 of 1,038
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
The role of dietary fatty acids in the pathology of metabolic syndrome
Lottenberg, A. M., Afonso, M. D. S., Lavrador, M. S. F., Machado, R. M., & Nakandakare, E. R. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.03.004 · Cited by 220
“lipoproteins in NAFLD patients are nonesterified fatty acids derived from adipose tissue lipolysis [76].”
Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226
“A further possibility, consistent with the correlation we observed between effects on IHL and HBA1c, is that the effects on IHL are secondary to improved glucose tolerance, with reduced hyperinsulinemia (and perhaps reduced hyperglycaemia), reducing the increased rate of hepatocyte lipogenesis characteristic of these…”
Endoplasmic Reticulum Stress in Nonalcoholic Fatty Liver Disease
Pagliassotti, M. J. (2012) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071811-150644 · Cited by 220
Ziolkowska, S., Binienda, A., Jabłkowski, M., Szemraj, J., & Czarny, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011128 · Cited by 207
Regulation of lipogenesis by cyclin-dependent kinase 8–mediated control of SREBP-1
Zhao, X., Feng, D., Wang, Q., Abdulla, A., Xie, X.-J., Zhou, J., Sun, Y., Yang, E. S., Liu, L.-P., Vaitheesvaran, B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61462 · Cited by 213
Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes
Wree, A., Kahraman, A., Gerken, G., & Canbay, A. (2011) · Digestion · doi:10.1159/000318741 · Cited by 215
“The pathogenesis of NAFLD and especially NASH is currently in the focus of many studies. FA Transport Proteins and the Development of Simple Steatosis (NAFL)FFAs play a pivotal role in the development of simple hepatic steatosis. The oral intake of fat and the subsequent lipolysis in visceral adipose tissue lead to an…”
BackgroundNon-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome
Moore, J. B. (2010) · Proceedings of the Nutrition Society · doi:10.1017/s0029665110000030 · Cited by 217
“(43) 26 Stable isotope research in NAFLD patients has shown that, although 60% of the TAG in the 27 liver comes from the peripheral NEFA pool, elevations in fasting de novo lipogenesis also 28 contribute significantly.((44)) Additional work has observed both an increase in adipose lipolysis, and 29 increased VLDL-TAG…”
BackgroundIntestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q.-H., & Di Ciaula, A. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 211
“Circulating FFA represent about 60% of the total pool and are generated from the lipolysis of triglycerides (TG) in adipose tissue [217].”
BackgroundThe role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease
Nomura, K., & Yamanouchi, T. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.09.006 · Cited by 211
“This process is further enhanced by synergy with insulin resistance and/or obesity [24,25].”
BackgroundBoudaba, N., Marion, A., Huet, C., Pierre, R., Viollet, B., & Foretz, M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.008 · Cited by 213
“Because HFD-induced fatty liver results mainly from an increase in lipid uptake from the diet (Donnelly et al., 2005; Duarte et al., 2014),we evaluated the effect of AMPK ablation in aP2-nSREBP-1c transgenic mice, which displays exaggerated de novo lipogenesis and ectopic lipid accumulation in the liver (Shimomura et…”
BackgroundLawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217
Endoplasmic reticulum proteostasis in hepatic steatosis
Baiceanu, A., Mesdom, P., Lagouge, M., & Foufelle, F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.124 · Cited by 212
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 204
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Makri, E., Goulas, A., & Polyzos, S. A. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.11.010 · Cited by 204
Lipodystrophy: metabolic insights from a rare disorder
Huang-Doran, I., Sleigh, A., Rochford, J. J., O'Rahilly, S., & Savage, D. B. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0272 · Cited by 215
“This also appears to be true in obese patients with fatty liver (Donnelly et al. 2005) and in diabetic offspring (Petersen et al.”
BackgroundWang, Q., Jiang, L., Wang, J., Li, S., Yu, Y., You, J., Zeng, R., Gao, X., Rui, L., Li, W., et al. (2009) · Hepatology · doi:10.1002/hep.22774 · Cited by 213
Stanhope, K. L., Schwarz, J.-M., & Havel, P. J. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283613bca · Cited by 203
“[29] shows that in patients with nonalcoholic fatty liver disease (NAFLD), 26% of both intrahepatic fat and VLDLtriglyceride are made de novo [29].”
BackgroundAdipose tissue: between the extremes
Vegiopoulos, A., Rohm, M., & Herzig, S. (2017) · The EMBO Journal · doi:10.15252/embj.201696206 · Cited by 209
“This is a major contributor to the accumulation of lipids in the liver leading to non-alcoholic fatty liver disease, which can progress to non-alcoholic steatohepatitis involving inflammation and fibrosis (Donnelly et al , 2005).”
Tillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 213
“Maximal reduction of liver fat appears to require both inhibition of hepatic de novo lipogenesis and suppression of adipose tissue lipolysis (51, 52).”
BackgroundPerseghin, G., Lattuada, G., De Cobelli, F., Esposito, A., Belloni, E., Ntali, G., Ragogna, F., Canu, T., Scifo, P., Del Maschio, A., et al. (2008) · Hepatology · doi:10.1002/hep.21983 · Cited by 210
ChREBP regulates fructose-induced glucose production independently of insulin signaling
Kim, M.-S., Krawczyk, S. A., Doridot, L., Fowler, A. J., Wang, J. X., Trauger, S. A., Noh, H.-L., Kang, H. J., Meissen, J. K., Blatnik, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81993 · Cited by 212
“These studies do not address the observation that hyperinsulinemia fails to suppress hepatic glucose-6-phosphatase ( G6PC ) expression in insulin-resistant humans (12), a condition where increased DNL in association with steatosis and hypertriglyceridemia is readily apparent (13, 14).”
BackgroundLiver-Specific Activation of AMPK Prevents Steatosis on a High-Fructose Diet
Woods, A., Williams, J. R., Muckett, P. J., Mayer, F. V., Liljevald, M., Bohlooly-Y, M., & Carling, D. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.011 · Cited by 204
Sevastianova, K., Santos, A., Kotronen, A., Hakkarainen, A., Makkonen, J., Silander, K., Peltonen, M., Romeo, S., Lundbom, J., Lundbom, N., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.038695 · Cited by 211
CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing
Zeng, H., Qin, H., Liao, M., Zheng, E., Luo, X., Xiao, A., Li, Y., Chen, L., Wei, L., Zhao, L., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101428 · Cited by 211
“These accumulated lipids may arise via increased de novo lipogenesis (DNL), esterification of plasma free fatty acids (FFA), or dietary fatty acids intake [4].”
BackgroundDe novo lipogenesis in metabolic homeostasis: More friend than foe?
Solinas, G., Borén, J., & Dulloo, A. G. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.004 · Cited by 197
“stored in the liver of patients with NAFLD has been quantified in an elegant study using multiple stable isotopes to trace the different sources of liver fat [10].”
BackgroundInfluentialLiver and diabetes. A vicious circle
Loria, P., Lonardo, A., & Anania, F. (2013) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01031.x · Cited by 208
Role of DGAT enzymes in triacylglycerol metabolism
Bhatt-Wessel, B., Jordan, T. W., Miller, J. H., & Peng, L. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.08.001 · Cited by 203
Mechanisms of Lipotoxicity in NAFLD and Clinical Implications
Ibrahim, S. H., Kohli, R., & Gores, G. J. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31822578db · Cited by 199
“FFAs Circulating FFAs derived from adipose tissue lipolysis play a critical role in the development of steatosis in NAFLD, contributing to 60% of hepatic fat content (20,21).”
BackgroundBiomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease
Mato, J. M., Alonso, C., Noureddin, M., & Lu, S. C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i24.3009 · Cited by 199
Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04367-1 · Cited by 179
“During MAFLD, FAs from different sources (such as dietary, DNL, and lipolysis) are utilized in hepatocytes to produce TGs, contributing to liver fat accumulation [28, 29].”
BackgroundTherapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
“DNL occurs in hepatocytes via the formation of fatty acids from free glucose and fructose, and it is a major contributor to hepatic lipid accumulation 36,37 .”
Nonalcoholic fatty liver disease: Evolving paradigms
Lonardo, A., Nascimbeni, F., Maurantonio, M., Marrazzo, A., Rinaldi, L., & Adinolfi, L. E. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6571 · Cited by 197
Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease
de Gregorio, E., Colell, A., Morales, A., & Marí, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113858 · Cited by 197
“This deposition is caused by an imbalance in the control of liver lipids which, in turn, is caused by an increase of fatty acids/triglycerides uptake and/or enhanced de novo lipogenesis, together with an impaired fatty acids β-oxidation, and/or decreased export through very low-density lipoprotein (VLDL) particles [28…”
BackgroundMolecular mechanisms in MASLD/MASH-related HCC
Wang, X., Zhang, L., & Dong, B. (2025) · Hepatology · doi:10.1097/hep.0000000000000786 · Cited by 169
Marchisello, S., Di Pino, A., Scicali, R., Urbano, F., Piro, S., Purrello, F., & Rabuazzo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081948 · Cited by 190
Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver
Fletcher, J. A., Deja, S., Satapati, S., Fu, X., Burgess, S. C., & Browning, J. D. (2019) · JCI Insight · doi:10.1172/jci.insight.127737 · Cited by 194
“This may be clinically relevant, given that impaired ketogenesis in rodents is sufficient to exacerbate steatosis, stimulate the TCA cycle, increase gluconeogenesis and DNL, and promote liver injury — all characteristic features of NAFLD and NASH (23, 24).”
BackgroundAdiels, M., Westerbacka, J., Soro-Paavonen, A., Häkkinen, A. M., Vehkavaara, S., Caslake, M. J., Packard, C., Olofsson, S. O., Yki-Järvinen, H., Taskinen, M. R., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0790-1 · Cited by 198
“Overall, the influx of NEFA from adipose tissue to the liver normally accounts for 60–80% of the hepatic TG [24].”
BackgroundParlati, L., Régnier, M., Guillou, H., & Postic, C. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100346 · Cited by 167
Non‐alcoholic fatty liver disease from pathogenesis to management: an update
Musso, G., Gambino, R., & Cassader, M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00657.x · Cited by 196
“Stable isotope technique demonstrated that 59% of hepatic TG derive from adipose tissue FFA spill-over, 26% from DNL and 15% from dietary fat in NAFLD (35).”
MethodMetabolic implications of pancreatic fat accumulation
Wagner, R., Eckstein, S. S., Yamazaki, H., Gerst, F., Machann, J., Jaghutriz, B. A., Schürmann, A., Solimena, M., Singer, S., Königsrainer, A., et al. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00573-3 · Cited by 185
USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma
Ning, Z., Guo, X., Liu, X., Lu, C., Wang, A., Wang, X., Wang, W., Chen, H., Qin, W., Liu, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29846-9 · Cited by 187
Kotronen, A., Velagapudi, V. R., Yetukuri, L., Westerbacka, J., Bergholm, R., Ekroos, K., Makkonen, J., Taskinen, M.-R., Orešič, M., & Yki-Järvinen, H. (2009) · Diabetologia · doi:10.1007/s00125-009-1282-2 · Cited by 198
“In individuals with a fatty liver, the contribution of TGs derived from de novo lipogenesis to both hepatic and VLDL TGs is significantly increased [27, 31].”
BackgroundEndocannabinoids in liver disease
Tam, J., Liu, J., Mukhopadhyay, B., Cinar, R., Godlewski, G., & Kunos, G. (2011) · Hepatology · doi:10.1002/hep.24077 · Cited by 194
“4 These reviewed findings suggest that CB1 antagonists could be effective in the treatment of both AFLD and NAFLD.”
InfluentialDentin, R., Tomas-Cobos, L., Foufelle, F., Leopold, J., Girard, J., Postic, C., & Ferré, P. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.019 · Cited by 177
“Of the TG content accounted for in the liver of NAFLD patients, 60% arise from non-esterified fatty acids (NEFA), 10% from the diet, and close to 30% from lipogenesis [1], underlying the importance of de novo fat synthesis in the NAFLD pathology [2].”
BackgroundPaniagua, J. A. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i19.483 · Cited by 197
JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis
Cazanave, S. C., Mott, J. L., Elmi, N. A., Bronk, S. F., Werneburg, N. W., Akazawa, Y., Kahraman, A., Garrison, S. P., Zambetti, G. P., Charlton, M. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022491 · Cited by 191
Schreuder, T. C., Verwer, B. J., Nieuwkerk, C. M. V., & Mulder, C. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2474 · Cited by 191
A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
Skat‐Rørdam, J., Højland Ipsen, D., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13190 · Cited by 192
“In healthy individuals, DNL only contributes to ~5% of the total intrahepatic triglycerides; however, in NAFLD patients, this number increases to 15%‐23%, indicating an up‐regulation of DNL, and also suggesting that the majority of intrahepatic triglycerides in NAFLD patients originate from reduced secretion and/or in…”
BackgroundHepatic lipid droplet homeostasis and fatty liver disease
Seebacher, F., Zeigerer, A., Kory, N., & Krahmer, N. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.04.011 · Cited by 190
“This leads to a paradox: under conditions of exogenous lipid overflow, de novo lipogenesis is strongly upregulated, contributing to the pathogenesis of NAFLD (26).”
BackgroundModulation of hepatic steatosis by dietary fatty acids
Ferramosca, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1746 · Cited by 184
Negi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Luci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
“This sustained inflammation mediates insulin-resistance and provides a contributing link between its development and NAFLD (25).”
BackgroundParnell, J. A., Raman, M., Rioux, K. P., & Reimer, R. A. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02730.x · Cited by 189
“The contribution of de novo lipogenesis to hepatic TG is considered low in healthy humans, however, has been reported to account for 26% of liver TG content in NAFLD patients with hyperinsulinemia (51).”
BackgroundPathogenesis of Non-alcoholic Steatohepatitis: Human Data
Edmison, J., & McCullough, A. J. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.02.011 · Cited by 193
Hepatic Steatosis as a Marker of Metabolic Dysfunction
Fabbrini, E., & Magkos, F. (2015) · Nutrients · doi:10.3390/nu7064995 · Cited by 188
“In non-obese healthy subjects, hepatic de novo lipogenesis in the fasting and postprandial states typically accounts for ≤5% and ≤10% of all fatty acids incorporated in IHTG and VLDL-triglyceride, respectively [95,96], but its contribution can be as much as 3–5 times greater in patients with NAFLD, accounting for 15%…”
BackgroundInfluence of liver cancer on lipid and lipoprotein metabolism
Jiang, J., Nilsson-Ehle, P., & Xu, N. (2006) · Lipids in Health and Disease · doi:10.1186/1476-511x-5-4 · Cited by 196
Ashino, N. G., Saito, K. N., Souza, F. D., Nakutz, F. S., Roman, E. A., Velloso, L. A., Torsoni, A. S., & Torsoni, M. A. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.12.011 · Cited by 187
“De novo lipogenesis contributes significantly to hepatic accumulation of TG in NAFLD [28], and in this condition, the amounts of enzymes of the FA biosynthesis pathway may be increased.”
BackgroundNonalcoholic fatty liver disease
Krawczyk, M., Bonfrate, L., & Portincasa, P. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.08.005 · Cited by 187
“[24] Thus, intrahepatic accumulation of triglycerides can result from at least three pathogenetic moments depicted in Table 3, [25] and involving, from time to time, metabolic factors, membrane/nuclear receptors and hormones or drugs.”
BackgroundHomeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
Chao, H.-W., Chao, S.-W., Lin, H., Ku, H.-C., & Cheng, C.-F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020298 · Cited by 180
“Enhanced de novo lipogenesis abnormally has been reported in patients with insulin resistance and contribute to a critical biochemical pathway for the pathogenesis of NAFLD [57].”
BackgroundKathirvel, E., Morgan, K., Nandgiri, G., Sandoval, B. C., Caudill, M. A., Bottiglieri, T., French, S. W., & Morgan, T. R. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00249.2010 · Cited by 186
Transcriptional Regulation of Bim by FoxO3A Mediates Hepatocyte Lipoapoptosis
Barreyro, F. J., Kobayashi, S., Bronk, S. F., Werneburg, N. W., Malhi, H., & Gores, G. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704391200 · Cited by 190
Nonalcoholic fatty liver disease in type 2 diabetes mellitus
Cusi, K. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283293015 · Cited by 185
Pathophysiological mechanisms underlying MAFLD
Kuchay, M. S., Choudhary, N. S., & Mishra, S. K. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.026 · Cited by 177
Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
Ramanathan, R., Ali, A. H., & Ibdah, J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137280 · Cited by 171
“lipogenesis (DNL) activation, and a high-calorie and/or -fat diet [36].”
BackgroundInfluentialWada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., & Sasaoka, T. (2010) · Endocrinology · doi:10.1210/en.2009-0869 · Cited by 189
Current concepts in the pathogenesis of nonalcoholic fatty liver disease
Méndez‐Sánchez, N., Arrese, M., Zamora‐Valdés, D., & Uribe, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01483.x · Cited by 184
“The sources of hepatic triglycerides are markedly different in NAFLD patients compared with the normal population; only 60% of hepatic triglycerides arise from FFA, while 25% come from hepatic DNL and 15% from dietary fats (14).”
BackgroundGao, R., Li, Y., Xu, Z., Zhang, F., Xu, J., Hu, Y., Yin, J., Yang, K., Sun, L., Wang, Q., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000279 · Cited by 175
“[5,6] In general, acetyl-CoA derived from metabolic processes is converted to malonyl-CoA by acetyl-CoA carboxylase (ACC), which is used by fatty acid synthase (FASN) to generate palmitate.”
BackgroundZeng, S., Wang, Y., Chen, C., Kim, H., Liu, X., Jiang, M., Yu, Y., Kafuti, Y. S., Chen, Q., Wang, J., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202316487 · Cited by 186
Morris, E. M., Meers, G. M. E., Booth, F. W., Fritsche, K. L., Hardin, C. D., Thyfault, J. P., & Ibdah, J. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00169.2012 · Cited by 186
“However, the dyslipidemia associated with the metabolic syndrome and type 2 diabetes is the result of increased VLDL secretion rate and is directly associated with liver fat content (2, 3, 7, 36, 39).”
BackgroundLan, T., Yu, Y., Zhang, J., Li, H., Weng, Q., Jiang, S., Tian, S., Xu, T., Hu, S., Yang, G., et al. (2021) · Hepatology · doi:10.1002/hep.31749 · Cited by 187
“The presence of lipid droplets containing TGs in hepatocytes is a hallmark of NAFLD, and multiple genes involved in lipogenesis, fatty acid uptake and oxidation contribute to this phenomenon (23).”
BackgroundAdipose tissue and metabolic syndrome: too much, too little or neither
Grundy, S. M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12519 · Cited by 187
Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis
Baker, S. S., Baker, R. D., Liu, W., Nowak, N. J., & Zhu, L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009570 · Cited by 184
“De novo lipogenesis and dietary fatty acids are also significant sources of fat [5].”
BackgroundDrug metabolism alterations in nonalcoholic fatty liver disease
Merrell, M. D., & Cherrington, N. J. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.577781 · Cited by 181
“It is estimated that 60% of hepatic fat content comes from circulating fatty acids, not dietary content (Donnelly et al., 2005).”
BackgroundA fresh look at NASH pathogenesis. Part 1: The metabolic movers
Larter, C. Z., Chitturi, S., Heydet, D., & Farrell, G. C. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06253.x · Cited by 180
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R., & Sanyal, A. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 168
“biopsies, sources of intrahepatic triglycerides have been attributed mainly to circulating fatty acids (approximately 59%), DNL (approximately 26%) and dietary fatty acids (approximately 15%) in NAFLD.(54,55) DNL is estimated to be threefold higher in NAFLD compared with controls, whereas the production of fatty acids…”
BackgroundInfluentialAntioxidant dietary approach in treatment of fatty liver: New insights and updates
Ferramosca, A., Di Giacomo, M., & Zara, V. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i23.4146 · Cited by 180
Zonation of glucose and fatty acid metabolism in the liver: Mechanism and metabolic consequences
Hijmans, B. S., Grefhorst, A., Oosterveer, M. H., & Groen, A. K. (2014) · Biochimie · doi:10.1016/j.biochi.2013.06.007 · Cited by 169
“ysis [52].”
BackgroundInfluentialKotronen, A., Seppänen‐Laakso, T., Westerbacka, J., Kiviluoto, T., Arola, J., Ruskeepää, A., Yki‐Järvinen, H., & Orešič, M. (2010) · Obesity · doi:10.1038/oby.2009.326 · Cited by 179
“In insulin-resistant subjects with a fatty liver, stable isotope tracer studies have suggested that the production of saturated fatty acids via de novo lipogenesis is 5-fold higher as compared to healthy subjects (10,11).”
BackgroundTherapeutic Landscape for NAFLD in 2020
Neuschwander-Tetri, B. A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.051 · Cited by 184
SREBP-1c and lipogenesis in the liver: an update
Ferré, P., Phan, F., & Foufelle, F. (2021) · Biochemical Journal · doi:10.1042/bcj20210071 · Cited by 162
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024) · Liver International · doi:10.1111/liv.15930 · Cited by 171
“28 These data are also consistent with earlier work showing that free T3, via THR-β , directly increased expression of sterol regulatory element binding transcription factor (Srebf1), the master transcriptional regulator of DNL. 29 In sum, these data indicate that lipid excess in primary…”
MethodPostprandial metabolism of meal triglyceride in humans
Lambert, J. E., & Parks, E. J. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.01.006 · Cited by 182
“-PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript modulate disease risk in other chronic conditions such as obesity [8], type 2 diabetes [9,10], and non-alcoholic fatty liver disease, NAFLD [11].”
InfluentialSelf-citationFatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer
Menendez, J. A., Vazquez-Martin, A., Ortega, F. J., & Fernandez-Real, J. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115352 · Cited by 181
Pathophysiology of Non Alcoholic Fatty Liver Disease
Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Svegliati-Baroni, G., Valenti, L., & Bonino, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122082 · Cited by 170
“In addition, patients with NAFLD have increased hepatic synthesis of palmitate through DNL, and this increases the risk of lipotoxicity and cell damage [25,93].”
BackgroundDutkowski, P., Schlegel, A., Slankamenac, K., Oberkofler, C. E., Adam, R., Burroughs, A. K., Schadde, E., Müllhaupt, B., & Clavien, P.-A. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318272dea2 · Cited by 179
Seo, E., Kang, H., Choi, H., Choi, W., & Jun, H. (2019) · Aging Cell · doi:10.1111/acel.12895 · Cited by 173
Fang, K., Wu, F., Chen, G., Dong, H., Li, J., Zhao, Y., Xu, L., Zou, X., & Lu, F. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-019-2671-9 · Cited by 173
Glucocorticoids and non-alcoholic fatty liver disease
Woods, C. P., Hazlehurst, J. M., & Tomlinson, J. W. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.07.020 · Cited by 171
“60% of liver fat content in NAFLD comes from NEFAs generated from adipose tissue (14).”
BackgroundVillanueva, C. J., Monetti, M., Shih, M., Zhou, P., Watkins, S. M., Bhanot, S., & Farese, R. V. (2009) · Hepatology · doi:10.1002/hep.22980 · Cited by 175
Zhang, F., Zhao, S., Yan, W., Xia, Y., Chen, X., Wang, W., Zhang, J., Gao, C., Peng, C., Yan, F., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.013 · Cited by 175
“Increased hepatic de novo lipogenesis and resultant ectopic lipid deposition contributes to liver injury in obese individuals (Donnelly et al., 2005).”
BackgroundOf mice and men: The physiological role of adipose triglyceride lipase (ATGL)
Schreiber, R., Xie, H., & Schweiger, M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.10.008 · Cited by 169
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.-D., Kyrou, I., Efstathopoulos, E., Randeva, H. S., & Kassi, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 165
“When hepatocytes are overloaded with lipids, physiologically minor pathways of β-oxidation in the peroxisomes and the ER are upregulated, thus increasing the hepatocyte reactive oxygen species (ROS) production [41,48] and generating highly reactive aldehyde by-products [49].”
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000226115.97436.c0 · Cited by 173
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Carbohydrate Sensing Through the Transcription Factor ChREBP
Ortega-Prieto, P., & Postic, C. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00472 · Cited by 162
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
Willebrords, J., Pereira, I. V. A., Maes, M., Crespo Yanguas, S., Colle, I., Van Den Bossche, B., Da Silva, T. C., de Oliveira, C. P. M. S., Andraus, W., Alves, V. A., et al. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.05.002 · Cited by 171
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Mendez-Sanchez, N., Cruz-Ramon, V. C., Ramirez-Perez, O. L., Hwang, J. P., Barranco-Fragoso, B., & Cordova-Gallardo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072034 · Cited by 172
“TGs are simple lipids that are composed of a glycerol molecule associated with three FFAs [41].”
BackgroundLaursen, T. L., Hagemann, C. A., Wei, C., Kazankov, K., Thomsen, K. L., Knop, F. K., & Grønbæk, H. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i2.138 · Cited by 176
Zhang, J., Zhao, Y., Xu, C., Hong, Y., Lu, H., Wu, J., & Chen, Y. (2014) · Scientific Reports · doi:10.1038/srep05832 · Cited by 172
Metadata
- Authors
- Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Parks, Elizabeth J.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-05-02
- Volume
- 115
- Issue
- 5
- Pages
- 1343-1351
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1087172
- OpenAlex
- W1985592156
- Semantic Scholar
- ed7633369ab77ee37699d391fe0fa59627da0df8
- Cited by
- 3,604
- References
- 50
- Citations by year
- 2026: 158 · 2025: 199 · 2024: 230 · 2023: 268 · 2022: 254 · 2021: 264 · 2020: 229 · 2019: 221 · 2018: 222 · 2017: 184 · 2016: 200 · 2015: 185 · 2014: 163 · 2013: 147 · 2012: 127
- FWCI
- 44.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- University of Minnesota
- National Institutes of Health (RR00400)
- National Institute of Diabetes and Digestive and Kidney Diseases (R03DK058286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (PAR-98-086)
- National Center for Research Resources (M01RR000400)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- non-alcoholic fatty liver disease, hepatic triglycerides, de novo lipogenesis, free fatty acids, VLDL, stable isotope tracers, fatty acid sources, hepatic lipid accumulation, obesity, hypertriglyceridemia, hyperinsulinemia
- MeSH terms
- Adult, Fatty Acids, Fatty Liver, Female, Humans, Lipoproteins, Liver, Male, Middle Aged, Time Factors, Triglycerides, Cholesterol, VLDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.